Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum effective dose of esketamine for preventing preoperative separation anxiety in children
ChiCTR2500096317Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in separation anxiety disorder (SAD) (6 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Minimum effective dose ED90 for preventing preoperative separation anxiety and Mask acceptance score. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
separation anxiety disorder (SAD)
Beyond the preview
Go deeper on ChiCTR2500096317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096317.